Wire · opportunities
FDA approves new brain cancer imaging agent from Telix
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 14 September 2026 · Fusion42 review
The FDA approved Pixclara, a new radioactive diagnostic PET imaging drug from Telix for distinguishing brain cancer recurrence from treatment effects, marking the first FDA-approved FET-PET agent for glioma in the U.S. This approval addresses a significant unmet need with broad access anticipated for adult and pediatric patients.
This Wire brief sits within Fusion42's coverage of Medtech, and 5 sources have reported it.
◆ ◆ The Wire takeaway
Your medtech product now faces new competition as Pixclara moves into the U.S. brain cancer imaging market with FDA backing. You need to reassess your market strategy immediately to address the expanded access that Telix gains for both adults and pediatric patients.
◆ Coverage
5 sources · 14 Sep 2026
◆ Related on Wire
◆ Topics